Recent Updates
Recently added Catalysts

VCH-759

Phase 1

Hepatitis C, Chronic | Small molecule | Infectious Disease |Vertex Pharmaceuticals Incorporated|Last Updated: Sep 24, 2009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLEDDMC
Total Trials1
Total Enrollment36

FDA Designations

No designations recorded

Clinical trial landscape

VCH-759 · 1 trial · 1 indication

Phase 1 1
NCT00389298A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.Hepatitis C, Chronic
COMPLETED36 Analytics
PHASE1COMPLETED
A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.
Hepatitis C, Chronic
NCT0038929836
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change in baseline HCV plasma RNA (i.e., viral load) at Day 11.

Secondary Endpoints

The change in plasma HCV RNA (i.e., viral load) over the treatment period (Days 1 to 10 will also be assessed.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
VCH-759 (BCH-27759)DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexMALE
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * 18 to 60 years of age * Body mass index (BMI) ≤ 30 * No evidence of cirrhosis or have liver fibrosis corresponding to Metavir Stages 0 to 3 * Subject's liver disease is stable (i.e., stable ALT and AST) * Serologic evidence of chronic hepatitis C-infection (anti-HCV in serum) ...

Countries:Canada
Unlock Eligibility Criteria

Frequently asked questions about VCH-759

What is VCH-759 used for in Hepatitis C?

VCH-759 is an investigational small molecule being developed for the treatment of chronic Hepatitis C. It is designed to target the Hepatitis C virus, though its specific molecular target has not been disclosed. The drug is currently in clinical development and is not yet approved by regulatory authorities.

What does VCH-759 target?

VCH-759 is a small molecule antiviral drug being developed to treat chronic Hepatitis C. While its exact molecular target has not been publicly specified, it is intended to act against the Hepatitis C virus. The drug is currently in Phase 1 clinical development and remains investigational.

Who makes VCH-759?

VCH-759 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company listed on the NASDAQ under the ticker symbol VRTX. The drug is currently in Phase 1 clinical development for the treatment of chronic Hepatitis C.

What phase is VCH-759 in?

VCH-759 is in Phase 1 clinical development. It is an investigational drug for chronic Hepatitis C and has not been approved by the FDA or any other regulatory agency. The drug is still in the early stages of clinical testing.

What clinical trials is VCH-759 in?

VCH-759 has been studied in one completed Phase 1 clinical trial, identified as NCT00389298. This proof-of-concept study enrolled 36 male participants in Canada and evaluated the drug for the treatment of chronic Hepatitis C. The trial was randomized and double-blind, though it did not use a control group.

Is VCH-759 the same as any other drug?

VCH-759 is a distinct investigational drug candidate developed by Vertex Pharmaceuticals. No alternative names for VCH-759 have been disclosed. It is being studied specifically for chronic Hepatitis C and is not known to be identical to any other approved or investigational medication.